Sustainability

Four hundred million packages of medicines a year carry our responsibility.

Scroll down

In Poland alone, that means one in eight packages sold in pharmacies and one in three used in hospitals. Our scale of supply defines the scale of obligation.

100%

Group entities

measuring their carbon footprint across Scope 1, 2 and 3 emissions in 2025.

Silver

74/100 EcoVadis rating ★★★★

for ZF Polpharma in 2025, in the top 15% of more than 130,000 companies assessed.

Severe accidents

at work places across the Group
in 2025.

5.5 bn

Daily therapies

provided by ZF Polpharma to patients in Poland and in international markets in 2025

Our commitment to sustainability spans more than a decade. Since then, we have continuously evolved our approach - increasing transparency, setting measurable goals, and integrating it into key business decisions. Today, we are implementing an ambitious ESG agenda. We recognize that sustainability is a journey that requires continuous improvement, innovation, and collaboration.

Magdalena Rzeszotalska

group head of Sustainability & ESG Department

management approach

Oversight of sustainability is led by the Group’s leadership.

The Management Board approves and implements the ESG Strategy, manages material ESG risks, tracks progress against ESG goals and secures the resources for sustainability initiatives. The Supervisory Board oversees how sustainability is integrated into the company's operational and strategic decisions.

Sustainable Development Comittee

Supports the Management Board in overseeing the company’s sustainability agenda. Acting in an advisory capacity, it provides guidance on the ESG Strategy, monitors progress against its objectives, and oversees related impacts, risks and opportunities.

oversight body

Sustainability & ESG Department

Reports directly to the CFO of the Polpharma Group. Coordinates day-to-day ESG activities across business areas, supports strategy execution and leads the Group’s ESG reporting process.

executive function

Business Area
Implementation

Strategy goals are assigned to the relevant functions, including production, procurement, R&D, HR and commercial. Each function is responsible for delivery, with progress reported annually against the KPIs of the current strategy cycle.

implementation

“We believe that strong financial performance and sustainable development go hand in hand. Sustainability is not a separate agenda - it is embedded in how we run our business, allocate capital, and create long-term value. “

wojciech rosa, Group Chief financial Officer

ESG Strategy 2026–2030

By 2030 we will broaden access to treatment while shrinking the footprint of making it.

Three impact areas: access to health, environmental impact, and company culture, stand on a foundation of responsible business processes. The ESG Strategy 2026–2030 model presented below, together with the focus areas assigned to each pillar, provides a common framework for the entire Polpharma Group.

We help people live healthy lives in a healthy world.

Access to health

Environmental impact

Organizational culture

Responsible business processess

Access to health

We increase access to effective treatment and health education

Wide access and security of drug supply

New products meeting patients' and consumers' needs

Education of medical community

Prevention and education for patients

Collaboration with scientific community

Environmental impact

We minimize environmental footprint of processes and products

Energy transformation

Supply chain decarbonization

Minimization of pollution

Reducing water consumption

Circular economy

Organizational culture

We foster an inclusive, growth-oriented culture built on openness, dialogue and continuous learning

Work safety

A culture of openness and dialogue

Power skills and learning organization

Physical and mental health and wellbeing

Diversity and inclusion

Responsible business processess

We strengthen responsible business standards across the entire value chain.

Quality and safety of products

Human rights

Ethics and compliance

Sustainable supply chain

ESG risk management

Verification & reporting

We are committed to transparency.

EcoVadis has assessed our biggest company – ZF Polpharma – annually since 2022. Polpharma also discloses its environmental performance through CDP.

EcoVadis rating

Silver

2025 score 74/100, Silver Medal

top 15% of more than 130,000 companies  assessed worldwide

/100

2023

/100

2024

/100

2025

Carbon Disclousure Project rating

Climate change rating

for ZF Polpharma’s environmental performance in 2025